Intravitreal steroids have been widely used in the treatment of various ocular pathologies including macular edema and noninfectious uveitis.Ozurdex (dexamethasone intravitreal implant 0.7 mg ...

--Adverum Biotechnologies, Inc., a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced preliminary safety and ...

Dexamethasone implants appear to be the best treatment for persistent or recurrent macular edema that often occurs in patients with uveitis, findings from a new study show. The 12-week ...

June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after ...

Oct 30 (Reuters) - Allergan Plc- * Allergan receives approval for Ozurdex® (dexamethasone intravitreal implant 0.7 mg) in China for the treatment of retinal vein occlusion (RVO) ...

Ozurdex, which is used in the treatment of macular oedema, was approved in the United States in June 2009, and the European Medicines Agency's positive recommendation should allow the drug to get ...